TITLE:
Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

CONDITION:
Advanced Non Small Cell Lung Cancer

INTERVENTION:
Tarceva (Trademark) (erlotinib HCl, OSI-774)

SUMMARY:

      The purpose of this study is to determine if erlotinib will improve disease at doses that
      produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.
    

DETAILED DESCRIPTION:

      Only patients with 0 to 1 performance status on the ECOG scale are eligible.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of Stage IIIB or IV non-small cell lung cancer (histological or
             cytological).

          -  Received prior chemotherapy treatment for advanced, metastatic non-small cell lung
             cancer.

          -  Measurable disease per RECIST criteria.

          -  Adequate bone marrow, hepatic and renal function.

        Exclusion Criteria:

          -  Breast cancer or skin cancer at any time in the past or any other cancer in the past
             5 years.

          -  Brain metastases that are unstable, require steroids, are life-threatening or
             required radiation in the last 28 days.

          -  Known hypersensitivity to minocycline.

          -  History of serious cardiac disease that is not controlled.

          -  Serious eye conditions.

          -  Prior treatment with inhibitors of EGFR of any kind.
      
